SARS-CoV-2疫苗接种在退伍军人炎症性肠病队列中的有效性
该回顾性队列研究纳入14697例炎症性肠病(IBD)退伍军人患者,评估COVID-19疫苗接种对后续感染的有效性。完全接种(第二剂后>7天)相对未接种的感染风险降低69%(HR 0.31,95%CI 0.17-0.56;P<.001),疫苗有效性为80.4%。
要点
- 完全接种与感染风险降低69%相关(HR 0.31)。
- 疫苗有效性估计为80.4%。
- 部分接种未显示与感染风险降低显著相关。
核心结论
- 完全接种SARS-CoV-2疫苗在广泛暴露于免疫抑制药物的IBD队列中有效性约为80.4%。
研究设计与样本
- 回顾性队列研究,纳入退伍军人健康管理局14697例IBD患者。
- 疫苗接种状态作为时间更新暴露,采用逆概率加权和Cox回归。
主要发现
- 未接种者SARS-CoV-2感染粗比例为1.34%(197例),完全接种者为0.11%(7例)。
- 完全接种相对未接种的感染风险HR为0.31(95%CI 0.17-0.56;P<.001)。
- 部分接种状态与感染风险降低无显著关联。
关键数值与推荐
- 完全接种定义为第二剂后>7天。
- 疫苗有效性为80.4%。
临床怎么用
- 结果可能提高IBD患者和提供者接种疫苗的意愿。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly expanded; however, clinical trials excluded patients taking immunosuppressive medications such as those with inflammatory bowel disease (IBD). Therefore, we explored real-world effectiveness of coronavirus disease 2019 (COVID-19) vaccination on subsequent infection in patients with IBD with diverse exposure to immunosuppressive medications. METHODS: This was a retrospective cohort study of patients in the Veterans Health Administration with IBD diagnosed before December 18, 2020, the start date of the Veterans Health Administration patient vaccination program. IBD medication exposures included mesalamine, thiopurines, anti-tumor necrosis factor biologic agents, vedolizumab, ustekinumab, tofacitinib, methotrexate, and corticosteroid use. We used inverse probability weighting and Cox's regression with vaccination status as a time-updating exposure and computed vaccine effectiveness from incidence rates. RESULTS: The cohort comprised 14,697 patients, 7321 of whom received at least 1 vaccine dose (45.2% Pfizer, 54.8% Moderna). The cohort had median age 68 years, 92.2% were men, 80.4% were White, and 61.8% had ulcerative colitis. In follow-up data through April 20, 2021, unvaccinated individuals had the highest raw proportion of SARS-CoV-2 infection (197 [1.34%] vs 7 [0.11%] fully vaccinated). Full vaccination status, but not partial vaccination status, was associated with a 69% reduced hazard of infection relative to an unvaccinated status (hazard ratio, 0.31, 95% confidence interval, 0.17-0.56; P < .001), corresponding to an 80.4% effectiveness. CONCLUSIONS: Full vaccination (> 7 days after the second dose) against SARS-CoV-2 infection has an ∼80.4% effectiveness in a broad IBD cohort with diverse exposure to immunosuppressive medications. These results may serve to increase patient and provider willingness to pursue vaccination in these settings.
引用
- Khan N, Mahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. Gastroenterology. 2021. PMID: 34048782. doi:10.1053/j.gastro.2021.05.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。